Cutis Pharma and Dr. Reddy's Laboratories Announce Partnership

Pharmaceutical Cooperation Cutis Pharma and Dr. Reddy's Laboratories Announce Partnership

11.04.2016Editor: Dominik Stephan

Cutis Pharma, a specialty pharmaceutical company that has entered into Active Pharmaceutical Ingredient (API) supply and joint development agreements with Dr Reddy’s Laboratories.to advance several programs in Cutis Pharma’s R&D portfolio, including RM-02, RM-03, and RM-06, toward FDA approval.

Related Companies

AZO GmbH + Co. KG

TRM Filter d.o.o.

Frewitt fabrique de machines SA

Wilmington, Massachusetts/USA – “This partnership has significant strategic benefits for both parties,” said Neal Muni, MD, MSPH, Chief Executive Officer of Cutis Pharma. “Dr. Reddy’s Laboratories breadth of expertise and international infrastructure provide great synergy to Cutis Pharma’s own R&D and commercial organizations and will be a significant catalyst in our plans to fast-track the development of three of our programs towards New Drug Application (NDA) filings.”

Deepak Sapra, Vice President & Global Head, CPS Business of Dr. Reddy’s Laboratories, said, “We continuously engage in research to find innovative solutions that address the unmet needs of patients and to create a robust healthcare ecosystem. The partnership with Cutis Pharma will further enhance and strengthen their R&D portfolio in bringing good health to millions in the country.”

“By leveraging the strengths of both parties, we look forward to expediting the development of three of our key R&D portfolio assets and maximizing commercial value of these programs in the United States as well as select international markets.” Muni said.

Unfold for details of your consent

Stand vom 23.03.2021

Naturally, we always handle your personal data responsibly. Any personal data we receive from you is processed in accordance with applicable data protection legislation. For detailed information please see our privacy policy.

Consent to the use of data for promotional purposes

I hereby consent to Vogel Communications Group GmbH & Co. KG, Max-Planckstr. 7-9, 97082 Würzburg including any affiliated companies according to §§ 15 et seq. AktG (hereafter: Vogel Communications Group) using my e-mail address to send editorial newsletters. A list of all affiliated companies can be found here

Newsletter content may include all products and services of any companies mentioned above, including for example specialist journals and books, events and fairs as well as event-related products and services, print and digital media offers and services such as additional (editorial) newsletters, raffles, lead campaigns, market research both online and offline, specialist webportals and e-learning offers. In case my personal telephone number has also been collected, it may be used for offers of aforementioned products, for services of the companies mentioned above, and market research purposes.

In case I access protected data on Internet portals of Vogel Communications Group including any affiliated companies according to §§ 15 et seq. AktG, I need to provide further data in order to register for the access to such content. In return for this free access to editorial content, my data may be used in accordance with this consent for the purposes stated here.

Right of revocation

I understand that I can revoke my consent at will. My revocation does not change the lawfulness of data processing that was conducted based on my consent leading up to my revocation. One option to declare my revocation is to use the contact form found at https://support.vogel.de. In case I no longer wish to receive certain newsletters, I have subscribed to, I can also click on the unsubscribe link included at the end of a newsletter. Further information regarding my right of revocation and the implementation of it as well as the consequences of my revocation can be found in the data protection declaration, section editorial newsletter.

(ID:43986844)

Pharmaceutical Cooperation Cutis Pharma and Dr. Reddy's Laboratories Announce Partnership

Subscribe to the newsletter now

Don't Miss out on Our Best Content

Consent to the use of data for promotional purposes